What is the mechanism of action of Pinealon?

Penetrates cells, enters the nucleus, and modulates gene expression. Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Penetrates cells, enters the nucleus, and modulates gene expression. The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What route should I use for Pinealon?

Pinealon is delivered by subq/intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

What are the safety considerations for Pinealon?

Excellent. Decades of safety data in Russian research. For healthspan and biological-age use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Pinealon's Short plasma; durable tissue effects pharmacokinetic profile and subq/intranasal administration route influence the side-effect profile in predictable ways.

How should Pinealon be stored and reconstituted?

Lyophilised Pinealon stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What class of compound is Pinealon?

Pinealon is classified as a Khavinson tripeptide (pineal-derived). Within this class, alternative names and analogues include Glu-Asp-Arg tripeptide. The class-level pharmacology shapes both the clinical applications and the safety profile; the longevity / hallmarks of aging literature treats Pinealon alongside its class peers when evaluating relative merits.

Home/ Compounds/ Pinealon

Pinealon

Longevity

Healthspan-relevant evaluation of Pinealon starts with mapping its mechanism to the hallmarks of aging and asking which of the nine hallmarks its primary pharmacology engages. Penetrates cells, enters the nucleus, and modulates gene expression Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators.. The Short plasma; durable tissue effects pharmacokinetic profile, the cycle-based 5-10 mg 1x daily for 10-20 day cycles dosing pattern, and the longevity-specific stack partners on adjacent hallmarks together produce the framework documented below.

Longevity / Hallmarks of Aging Applications

Nutrient SensingHallmarks of AgingMitochondrial BiogenesisHealthspan ExtensionInflammaging

Key Takeaways

Longevity lens: Pinealon maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Penetrates cells, enters the nucleus, and modulates gene expression.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 5-10 mg 1x daily for 10-20 day cycles dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

For longevity-relevant evaluation, Pinealon's mechanism is examined against the hallmarks of aging rather than against acute clinical endpoints. Penetrates cells, enters the nucleus, and modulates gene expression. Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators. The subsections below address the hallmarks mapping, cellular reprogramming layer, healthspan markers, and dosing-pattern conventions in longevity research.

Mapping to the hallmarks of aging

Pinealon's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Penetrates cells, enters the nucleus, and modulates gene expression. Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators. This places its dominant contribution in the core hallmarks (cellular and molecular) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after Pinealon cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cycle-based versus continuous dosing

Pinealon's longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Longevity / Hallmarks of Aging Applications

Senescence Modulation

For senescence modulation as a longevity-relevant endpoint, Pinealon is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Inflammaging

Inflammaging maps to one of the hallmarks of aging and is one of the dimensions on which Pinealon is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Cellular Reprogramming

Pinealon's contribution to cellular reprogramming as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Nutrient Sensing

For nutrient sensing as a longevity-relevant endpoint, Pinealon is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	5-10 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	3-10 mg	4–6 weeks initial cycle
Longevity focus	SubQ	5-10 mg	1x daily for 10-20 day cycles
Maintenance phase	SubQ	4-10 mg	Ongoing with periodic pauses

Dose timing for Pinealon is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Pinealon stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

Pinealon + Epithalon: Identified by Khavinson in St. Pairs naturally with Pinealon's mechanism in longevity / hallmarks of aging protocols.
Pinealon + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with Pinealon's mechanism in longevity / hallmarks of aging protocols.
Pinealon + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with Pinealon's mechanism in longevity / hallmarks of aging protocols.
Pinealon + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Pinealon's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Russian clinical trials; limited Western data

Excellent. Decades of safety data in Russian research.

Lens-specific safety considerations for longevity / hallmarks of aging use of Pinealon: Excellent. Decades of safety data in Russian research. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Pinealon — neuroprotective peptide

PMID 21424325

Pinealon vs Related Peptides

Compound	Profile	Onset	Best For
Pinealon	Khavinson tripeptide (pineal-derived)	Short plasma; durable tissue effects	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

How do I know if Pinealon is working?

Track outcome metrics that match the compound's primary mechanism: epigenetic age (DNA methylation panels), inflammatory markers (hsCRP, IL-6), metabolic flexibility (HbA1c, fasting insulin, HOMA-IR), body composition (DEXA), and subjective markers (sleep depth, recovery, well-being). Paired pre-post measurement around cycles is the standard framework.

Cycle-based or continuous dosing for longevity?

Longevity-research convention favours cycle-based and pulsatile interventions over indefinite continuous administration. Hormetic stimulation produces stronger systems-biology effects than sustained agonism for most longevity-relevant endpoints. Pinealon fits this framework with cycle lengths typical for its compound class.

Does Pinealon interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

When in life should I start Pinealon?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

What is the regulatory status of Pinealon?

Pinealon regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level russian clinical trials; limited western data. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does Pinealon map to the hallmarks of aging?

Pinealon's longevity relevance maps to specific hallmarks based on its mechanism. Penetrates cells, enters the nucleus, and modulates gene expression. Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators. For users tracking healthspan-relevant biomarkers across cycles, the relevant endpoints are determined by which hallmark the compound primarily targets — telomere maintenance, senescence modulation, mitochondrial biogenesis, autophagy induction, inflammaging, or epigenetic clock effects. The framework above identifies the dominant contribution.

Clinical Protocol

Start a Pinealon Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified Pinealon and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 418 Da
Sequence length: 3 aa
Half-life: Short plasma; durable tissue effects
WADA: Not on prohibited list
FDA: Unapproved
Research: Russian clinical trials; limited Western data

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Pinealon unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for Pinealon

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised